Treatment Strategies for Patients with Schizophrenia: Finding the Right Mix of Drug and Delivery to Prevent Relapse
neuroscienceCME WebcastPremiere Date: Friday, March 9, 2018
This activity offers CE credit for:%>
- Physicians (CME)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, March 9, 2019
Note: Credit Is No Longer Available
|John Lauriello, MD
Chair, Department of Psychiatry and Human Behavior
Sidney Kimmel Medical College at Thomas Jefferson University
Jefferson Enterprise Senior Vice President for Behavioral Health
This video is a replay of a plenary session from the 10th Annual Chair Summit Master Class for Neuroscience Professional Development held in New Orleans, LA on November 16-18, 2017.
At the end of this CE activity, participants should be able to:
- Implement treatment planning with a goal of recovery in at least 60% of patients with schizophrenia.
- Incorporate into practice management strategies that engage the patient and family/caregivers in improving adherence and reducing the risk of relapse in schizophrenia.
- Weigh the pros and cons of oral therapies versus long-acting injectables (LAIs) in achieving recovering when developing a treatment plan for patients with schizophrenia.
This activity is supported by an educational grant from Alkermes, Inc.
Physicians, physician assistants, nurse practitioners, pharmacists, certified case managers, social workers, and other nonphysical healthcare professionals with an interest in psychiatry, neurology, and the neurosciences.
CME Credit (Physicians):
CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, sue of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentation.
Dr. Lauriello reports that he receives grants as part of a clinical research site study headed and paid by Florida Atlantic University, sponsored by Otsuka. He is a consultant for Alkermes; and Teva Pharmaceuticals.
Howard Bliwise, MD (peer reviewer) has no disclosures to report.
Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.
Daniela V. DiBiase, MS (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff, CHCP (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff. No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).